Skip to main content
SpringerLink
Log in

Size of Residual Lymph Node Metastasis After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients Is Prognostic

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The prognostic significance of micrometastasis after neoadjuvant chemotherapy for locally advanced breast cancer is unknown. We examined the residual lymph node metastasis size in patients after treatment with neoadjuvant chemotherapy to determine the relevance of metastasis size on outcome.

Methods

Stage II/III breast cancer patients treated with neoadjuvant chemotherapy at our institution from 1991 to 2002 were included. We examined the relationship of postneoadjuvant chemotherapy lymph node metastasis size and number with distant disease-free survival (DDFS) and overall survival (OS).

Results

In 122 patients with a median follow-up of 5.4 years, we found not only that patients with an increasing number of residual positive nodes had progressively worse DDFS and OS (P < .0001 for both) compared with patients with negative nodes, but also that the size of the largest lymph node metastasis was associated with worse DDFS and OS (P < .0001 for both) in both univariate and multivariate analysis. Compared with negative nodes, even lymph node micrometastasis (<2 mm) was associated with worsened DDFS and OS (adjusted P = .02 and P = .005, respectively).

Conclusions

Residual micrometastatic disease in the axillary lymph nodes after neoadjuvant chemotherapy is predictive of worse prognosis than negative nodes. In this study, the lymph node metastasis size and the number of involved lymph nodes were independent powerful predictors of DDFS and OS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Cance WG, Carey LA, Calvo BF, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 2002;236:295–302

    Article  PubMed  Google Scholar 

  2. Carey LA, Metzger R, Dees EC, et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 2005;97:1137–42

    PubMed  Google Scholar 

  3. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672–85

    CAS  PubMed  Google Scholar 

  4. Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 1998;176:502–9

    Article  CAS  PubMed  Google Scholar 

  5. Botti C, Vici P, Lopez M, Scinto AF, Cognetti F, Cavaliere R. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am Coll Surg 1995;181:202–8

    CAS  PubMed  Google Scholar 

  6. Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002;80:4–11

    Article  PubMed  Google Scholar 

  7. McCready DR, Hortobagyi GN, Kau SW, Smith TL, Buzdar AU, Balch CM. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 1989;124:21–5

    CAS  PubMed  Google Scholar 

  8. Carey CA, Dees EC, Dressler L, et al. Response to trastuzumeb (Herceptin) given with paclitaxel (Taxol) immediately following 4 AC as initial therapy for breast cancer. Breast Cancer Res Treat 2002;76(Suppl 1):4292.

    Google Scholar 

  9. Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003;83:803–19.

    Article  PubMed  Google Scholar 

  10. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet 1990; 335:1565–8

    Google Scholar 

  11. Dowlatshahi K, Fan M, Bloom KJ, et al. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma: a preliminary study. Cancer 1999;86:990–6

    Article  CAS  PubMed  Google Scholar 

  12. Newman LA, Pernick NL, Adsay V, et al. Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome. Ann Surg Oncol 2003;10:734–9

    Article  PubMed  Google Scholar 

  13. Singh M, Capocelli KE, Marks JL, et al. Expression of vascular endothelial growth factor and proliferation marker MIB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer. Appl Immunohistochem Mol Morphol 2005;13:147–56

    CAS  PubMed  Google Scholar 

  14. Klauber-Demore N, Van Zee KJ, Linkov I, Borgen PI, Gerald WL. Biological behavior of human breast cancer micrometastases. Clin Cancer Res 2001;7:2434–9

    CAS  PubMed  Google Scholar 

  15. Ollila DW, Neuman HB, Sartor C, Carey LA, Klauber-Demore N. Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. Am J Surg 2005;190:371–5

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Supported by the University of North Carolina Breast Cancer SPORE award from the National Cancer Institute (P50-CA 58223), the National Institutes of Health (M01RR00046 [L.A.C.] and 1 K08 CA098034-01A2 [N.K.-D.]), and the Breast Cancer Research Foundation. Dr. Klauber-DeMore is the recipient of the American Society of Surgical Oncology/Breast Cancer Research Foundation Career Development Award and the Sidney Kimmel Translational Research Award.

Author information

Authors and Affiliations

  1. Department of Surgery, University of North Carolina at Chapel Hill, 3010 Old Clinic Building, CB #7213, Chapel Hill, North Carolina, 27599

    Nancy Klauber-DeMore MD, David W. Ollila MD, Benjamin F. Calvo MD & Hong Jin Kim MD

  2. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 102 Mason Farm Road, CB #7295, Chapel Hill, North Carolina, 27599

    Nancy Klauber-DeMore MD, David W. Ollila MD, Dominic T. Moore M.S, M.P.H., Benjamin F. Calvo MD, Hong Jin Kim MD, E. Claire Dees MD, Carolyn I. Sartor MD, Lynda R. Sawyer M.F.A., Mark Graham II MD & Lisa A. Carey MD

  3. Department of Biostatistics, University of North Carolina at Chapel Hill, McGavran-Greenberg Hall, CB #7420, Chapel Hill, North Carolina, 27599

    Dominic T. Moore M.S, M.P.H.

  4. Department of Pathology and Lab Medicine, University of North Carolina at Chapel Hill, 30145 Women and Children’s Hospital, CB #7525, Chapel Hill, North Carolina, 27599

    Chad Livasy MD

  5. Department of Medicine, University of North Carolina at Chapel Hill, 3009 Old Clinic Building, CB #7305, Chapel Hill, North Carolina, 27599

    E. Claire Dees MD, Mark Graham II MD & Lisa A. Carey MD

  6. Department of Radiation Oncology, University of North Carolina at Chapel Hill, 101 Manning Drive, CB #7512, Chapel Hill, North Carolina, 27599

    Carolyn I. Sartor MD

Authors
  1. Nancy Klauber-DeMore MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David W. Ollila MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dominic T. Moore M.S, M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chad Livasy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Benjamin F. Calvo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hong Jin Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Claire Dees MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carolyn I. Sartor MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lynda R. Sawyer M.F.A.
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mark Graham II MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lisa A. Carey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nancy Klauber-DeMore MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klauber-DeMore, N., Ollila, D.W., Moore, D.T. et al. Size of Residual Lymph Node Metastasis After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients Is Prognostic. Ann Surg Oncol 13, 685–691 (2006). https://doi.org/10.1245/ASO.2006.03.010

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2006.03.010

Keywords

Search

Navigation